S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
Laser breakthrough could send stock soaring 2,467% (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
Laser breakthrough could send stock soaring 2,467% (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Laser breakthrough could send stock soaring 2,467% (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
Laser breakthrough could send stock soaring 2,467% (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
Laser breakthrough could send stock soaring 2,467% (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Laser breakthrough could send stock soaring 2,467% (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
Laser breakthrough could send stock soaring 2,467% (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
Laser breakthrough could send stock soaring 2,467% (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Laser breakthrough could send stock soaring 2,467% (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
Laser breakthrough could send stock soaring 2,467% (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
Laser breakthrough could send stock soaring 2,467% (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Laser breakthrough could send stock soaring 2,467% (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
NASDAQ:RXDX

Prometheus Biosciences (RXDX) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$199.60
$199.98
50-Day Range
$192.50
$199.92
52-Week Range
$23.27
$199.98
Volume
1.86 million shs
Average Volume
913,102 shs
Market Capitalization
$9.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$162.70

Prometheus Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
18.6% Downside
$162.70 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.84) to ($4.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.71 out of 5 stars

Medical Sector

971st out of 974 stocks

Biotechnology Industry

25th out of 26 stocks


RXDX stock logo

About Prometheus Biosciences (NASDAQ:RXDX) Stock

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.


RXDX Stock News Headlines

Prometheus Biosciences (NASDAQ: RXDX)
Top Wellness Nasdaq Stock for 2023
Cutting-Edge Ai-Based Technology Is Set to Disrupt the Womens Wellness Space
As AI Explodes this Company Could Skyrocket
A game-changing device expected to hit the market soon may put this AI company on the map.
RBC Capital downgrades Prometheus Biosciences (RXDX) to a Hold
How to Tell Biotech’s Likely Winners From Losers
Healthcare Is Back. But Is It Here to Stay?
See More Headlines
Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Company Calendar

Last Earnings
5/09/2023
Today
9/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXDX
Fax
N/A
Employees
97
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$162.70
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$111.00
Forecasted Upside/Downside
-18.6%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$-141,750,000.00
Net Margins
-3,768.76%
Pretax Margin
-3,768.76%

Debt

Sales & Book Value

Annual Sales
$6.81 million
Book Value
$16.12 per share

Miscellaneous

Free Float
46,187,000
Market Cap
$9.56 billion
Optionable
Not Optionable
Beta
-0.49

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark C. McKenna (Age 43)
    Pres, CEO & Chairman
    Comp: $1.33M
  • Dr. Keith W. Marshall M.B.A. (Age 55)
    MBA, Ph.D., Chief Financial Officer
    Comp: $829.45k
  • Mr. Mark Stenhouse (Age 56)
    Chief Operating Officer
    Comp: $807.4k
  • Dr. Olivier Laurent Ph.D. (Age 51)
    Chief Scientific Officer & Head of R&D
  • Ms. Noel Kurdi
    VP of Investor Relations & Communications
  • Mr. Timothy K. Andrews Esq. (Age 44)
    Gen. Counsel & Sec.
  • Ms. Nori Ebersole (Age 59)
    Chief People Officer
  • Dr. Allison Luo M.D. (Age 50)
    Chief Medical Officer
  • Dr. Thierry Dervieux DABCC (Age 55)
    Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director
  • Mr. Chris Doughty
    Chief Bus. Officer













RXDX Stock - Frequently Asked Questions

Should I buy or sell Prometheus Biosciences stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares.
View RXDX analyst ratings
or view top-rated stocks.

What is Prometheus Biosciences' stock price forecast for 2023?

10 brokerages have issued 12 month price objectives for Prometheus Biosciences' stock. Their RXDX share price forecasts range from $111.00 to $200.00. On average, they anticipate the company's share price to reach $162.70 in the next year. This suggests that the stock has a possible downside of 18.6%.
View analysts price targets for RXDX
or view top-rated stocks among Wall Street analysts.

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.06. The biopharmaceutical company had revenue of $1.11 million for the quarter, compared to analysts' expectations of $0.46 million. Prometheus Biosciences had a negative trailing twelve-month return on equity of 33.50% and a negative net margin of 3,768.76%. The business's revenue for the quarter was down 71.8% on a year-over-year basis.

What ETF holds Prometheus Biosciences' stock ?

Vanguard Russell 2000 Growth ETF holds 27,868 shares of RXDX stock, representing 0.58% of its portfolio.

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD).

When did Prometheus Biosciences IPO?

(RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Prometheus Biosciences' stock symbol?

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

What is Prometheus Biosciences' stock price today?

One share of RXDX stock can currently be purchased for approximately $199.92.

How much money does Prometheus Biosciences make?

Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $9.56 billion and generates $6.81 million in revenue each year. The biopharmaceutical company earns $-141,750,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

Does Prometheus Biosciences have any subsidiaries?
The following companies are subsidiares of Prometheus Biosciences: Prometheus Laboratories Inc..
Read More
How can I contact Prometheus Biosciences?

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com.

This page (NASDAQ:RXDX) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -